IVA vs. PBYI, GALT, VERU, CAPR, ATOS, OGI, OMER, ZVRA, TRVI, and CDT
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Puma Biotechnology (PBYI), Galectin Therapeutics (GALT), Veru (VERU), Capricor Therapeutics (CAPR), Atossa Therapeutics (ATOS), Organigram (OGI), Omeros (OMER), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
Puma Biotechnology received 521 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 66.54% of users gave Puma Biotechnology an outperform vote.
Inventiva currently has a consensus target price of $17.00, indicating a potential upside of 394.19%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 72.41%. Given Inventiva's higher possible upside, research analysts plainly believe Inventiva is more favorable than Puma Biotechnology.
Inventiva has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
In the previous week, Inventiva had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Inventiva and 5 mentions for Puma Biotechnology. Inventiva's average media sentiment score of 0.63 beat Puma Biotechnology's score of 0.50 indicating that Inventiva is being referred to more favorably in the media.
19.1% of Inventiva shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Puma Biotechnology has a net margin of 6.79% compared to Inventiva's net margin of 0.00%. Puma Biotechnology's return on equity of 35.49% beat Inventiva's return on equity.
Puma Biotechnology has higher revenue and earnings than Inventiva.
Summary
Puma Biotechnology beats Inventiva on 8 of the 15 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
